<a target="_blank" href="https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms">We love to hear from our listeners. Send us a message. </a>On this week&apos;s episode of the Business of Biotech we speak with Rahul Aras, Ph.D., President and CEO at Iterion Therapeutics, about capital efficient drug development in oncology and progressing a novel therapeutic with relatively small funding amounts. Iterion is a clinical stage company developing cancer therapeutics targeting the Wnt/β-catenin pathway, a known signaling target in oncology, but one that has confounded drug development efforts for decades. Rahul talks about his path from academia to company building and early work in gene therapy, Iterion&apos;s partnership strategy, and operating a biotech in the Houston, Texas clinical hub. Access this and hundreds of episodes of the Business of Biotech videocast under the <a href='https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl'>Business of Biotech</a> tab at lifescienceleader.com. Subscribe to our monthly <a href='https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/'>Business of Biotech newsletter</a>. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: <a href='https://www.linkedin.com/in/bencomer/'>https://www.linkedin.com/in/bencomer/</a>

<description>&lt;p&gt;&lt;a target="_blank" href="https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms"&gt;We love to hear from our listeners. Send us a message. &lt;/a&gt;&lt;/p&gt;&lt;p&gt;On this week&amp;apos;s episode of the Business of Biotech we speak with Rahul Aras, Ph.D., President and CEO at Iterion Therapeutics, about capital efficient drug development in oncology and progressing a novel therapeutic with relatively small funding amounts. Iterion is a clinical stage company developing cancer therapeutics targeting the Wnt/β-catenin pathway, a known signaling target in oncology, but one that has confounded drug development efforts for decades. Rahul talks about his path from academia to company building and early work in gene therapy, Iterion&amp;apos;s partnership strategy, and operating a biotech in the Houston, Texas clinical hub. &lt;/p&gt;&lt;p&gt;Access this and hundreds of episodes of the &lt;b&gt;Business of Biotech videocast&lt;/b&gt; under the &lt;a href='https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl'&gt;&lt;b&gt;Business of Biotech&lt;/b&gt;&lt;/a&gt; tab at lifescienceleader.com. &lt;/p&gt; &lt;p&gt;Subscribe to our monthly &lt;a href='https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/'&gt;&lt;b&gt;Business of Biotech newsletter&lt;/b&gt;&lt;/a&gt;.&lt;br/&gt; &lt;br/&gt;Get in touch with &lt;b&gt;guest and topic suggestions&lt;/b&gt;: ben.comer@lifescienceleader.com&lt;br/&gt;&lt;br/&gt;Find &lt;b&gt;Ben Comer&lt;/b&gt; &lt;b&gt;on LinkedIn&lt;/b&gt;: &lt;a href='https://www.linkedin.com/in/bencomer/'&gt;https://www.linkedin.com/in/bencomer/&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;/p&gt;</description>

We love to hear from our listeners. Send us a message.  On this week's episode of the Business of Biotech we speak with Rahul Aras, Ph.D., President and CEO at Iterion Therapeutics, about capital efficient drug development in oncology and progressing a novel therapeutic with relatively small funding amounts. Iterion is a clinical stage company developing cancer therapeutics targeting the Wnt/β-catenin pathway, a known signaling target in oncology, but one that has confounded drug development ...

Developing Novel Cancer Drugs On A Budget With Iterion Therapeutics' Rahul Aras, Ph.D.

<a target="_blank" href="https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms">We love to hear from our listeners. Send us a message. </a>On this week&apos;s episode of the Business of Biotech, we&apos;re speaking with Thomas von Erlach, Ph.D., Cofounder and CEO at Vivtex, a company spun out of the Langer Lab at MIT that&apos;s focused on developing orally available biologics. The company announced a deal in late February &apos;26 with Novo Nordisk for up to $2.1 billion to develop next-gen oral drugs for obesity and diabetes, bringing the total number of Vivtex&apos;s partnerships to 10. Thomas shares his experiences working in the lab with Dr. Robert Langer, Ph.D., starting up Vivtex around his co-invention (a &quot;GI tract on a chip&quot;), building trust externally and securing the right partnerships, and using a strategic stealth period to refine Vivtex&apos;s platform technology before scaling it out. Access this and hundreds of episodes of the Business of Biotech videocast under the <a href='https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl'>Business of Biotech</a> tab at lifescienceleader.com. Subscribe to our monthly <a href='https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/'>Business of Biotech newsletter</a>. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: <a href='https://www.linkedin.com/in/bencomer/'>https://www.linkedin.com/in/bencomer/</a>

<description>&lt;p&gt;&lt;a target="_blank" href="https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms"&gt;We love to hear from our listeners. Send us a message. &lt;/a&gt;&lt;/p&gt;&lt;p&gt;On this week&amp;apos;s episode of the Business of Biotech, we&amp;apos;re speaking with Thomas von Erlach, Ph.D., Cofounder and CEO at Vivtex, a company spun out of the Langer Lab at MIT that&amp;apos;s focused on developing orally available biologics. The company announced a deal in late February &amp;apos;26 with Novo Nordisk for up to $2.1 billion to develop next-gen oral drugs for obesity and diabetes, bringing the total number of Vivtex&amp;apos;s partnerships to 10. Thomas shares his experiences working in the lab with Dr. Robert Langer, Ph.D., starting up Vivtex around his co-invention (a &amp;quot;GI tract on a chip&amp;quot;), building trust externally and securing the right partnerships, and using a strategic stealth period to refine Vivtex&amp;apos;s platform technology before scaling it out. &lt;/p&gt;&lt;p&gt;Access this and hundreds of episodes of the &lt;b&gt;Business of Biotech videocast&lt;/b&gt; under the &lt;a href='https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl'&gt;&lt;b&gt;Business of Biotech&lt;/b&gt;&lt;/a&gt; tab at lifescienceleader.com. &lt;/p&gt; &lt;p&gt;Subscribe to our monthly &lt;a href='https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/'&gt;&lt;b&gt;Business of Biotech newsletter&lt;/b&gt;&lt;/a&gt;.&lt;br/&gt; &lt;br/&gt;Get in touch with &lt;b&gt;guest and topic suggestions&lt;/b&gt;: ben.comer@lifescienceleader.com&lt;br/&gt;&lt;br/&gt;Find &lt;b&gt;Ben Comer&lt;/b&gt; &lt;b&gt;on LinkedIn&lt;/b&gt;: &lt;a href='https://www.linkedin.com/in/bencomer/'&gt;https://www.linkedin.com/in/bencomer/&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;/p&gt;</description>

We love to hear from our listeners. Send us a message.  On this week's episode of the Business of Biotech, we're speaking with Thomas von Erlach, Ph.D., Cofounder and CEO at Vivtex, a company spun out of the Langer Lab at MIT that's focused on developing orally available biologics. The company announced a deal in late February '26 with Novo Nordisk for up to $2.1 billion to develop next-gen oral drugs for obesity and diabetes, bringing the total number of Vivtex's partnerships to 10. Thomas s...

Making Biologics Orally Available With Vivtex's Thomas von Erlach, Ph.D.

<a target="_blank" href="https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms">We love to hear from our listeners. Send us a message. </a>On this week&apos;s episode of the Business of Biotech we speak with Monika Sumra, Ph.D., about how leadership, culture, and performance emerge from the environment and conditions inside an organization. Dr. Sumra, Founder and Managing Partner at Bunka, Inc., a management consulting firm and advisor to manufacturing-based organizations globally, explains how anthropology, CPIs, and rapid ethnography make culture measurable and operations faster, safer, and more reliable. Deploying a unique lens built on biosocial anthropology, she offers guidance on creating environments for sustainable performance in the complex life sciences industry. Access this and hundreds of episodes of the Business of Biotech videocast under the <a href='https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl'>Business of Biotech</a> tab at lifescienceleader.com. Subscribe to our monthly <a href='https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/'>Business of Biotech newsletter</a>. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: <a href='https://www.linkedin.com/in/bencomer/'>https://www.linkedin.com/in/bencomer/</a>

<description>&lt;p&gt;&lt;a target="_blank" href="https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms"&gt;We love to hear from our listeners. Send us a message. &lt;/a&gt;&lt;/p&gt;&lt;p&gt;On this week&amp;apos;s episode of the Business of Biotech we speak with Monika Sumra, Ph.D., about how leadership, culture, and performance emerge from the environment and conditions inside an organization. Dr. Sumra, Founder and Managing Partner at Bunka, Inc., a management consulting firm and advisor to manufacturing-based organizations globally, explains how anthropology, CPIs, and rapid ethnography make culture measurable and operations faster, safer, and more reliable. Deploying a unique lens built on biosocial anthropology, she offers guidance on creating environments for sustainable performance in the complex life sciences industry. &lt;/p&gt;&lt;p&gt;Access this and hundreds of episodes of the &lt;b&gt;Business of Biotech videocast&lt;/b&gt; under the &lt;a href='https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl'&gt;&lt;b&gt;Business of Biotech&lt;/b&gt;&lt;/a&gt; tab at lifescienceleader.com. &lt;/p&gt; &lt;p&gt;Subscribe to our monthly &lt;a href='https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/'&gt;&lt;b&gt;Business of Biotech newsletter&lt;/b&gt;&lt;/a&gt;.&lt;br/&gt; &lt;br/&gt;Get in touch with &lt;b&gt;guest and topic suggestions&lt;/b&gt;: ben.comer@lifescienceleader.com&lt;br/&gt;&lt;br/&gt;Find &lt;b&gt;Ben Comer&lt;/b&gt; &lt;b&gt;on LinkedIn&lt;/b&gt;: &lt;a href='https://www.linkedin.com/in/bencomer/'&gt;https://www.linkedin.com/in/bencomer/&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;/p&gt;</description>

We love to hear from our listeners. Send us a message.  On this week's episode of the Business of Biotech we speak with Monika Sumra, Ph.D., about how leadership, culture, and performance emerge from the environment and conditions inside an organization. Dr. Sumra, Founder and Managing Partner at Bunka, Inc., a management consulting firm and advisor to manufacturing-based organizations globally, explains how anthropology, CPIs, and rapid ethnography make culture measurable and operations fast...

An Anthropological Lens On Leadership In Life Sciences With Bunka's Monika Sumra, Ph.D. 

<a target="_blank" href="https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms">We love to hear from our listeners. Send us a message. </a>On this week&apos;s episode of the Business of Biotech, Jared Bauer, Cofounder and CEO at Seek Labs, talks about his adventures in company turnarounds, and setting up Seek Labs to improve patient diagnoses and to discover and develop new treatments for infectious diseases. Jared explains the technology convergence that was needed to build Seek Labs&apos; AI diagnostic and CRISPR-based therapeutics platform, an African Swine Fever proof-of-concept study that reduced viremia in pigs, mapping pathogens for rapid target design, and engaging with the FDA and global regulatory agencies.       Access this and hundreds of episodes of the Business of Biotech videocast under the <a href='https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl'>Business of Biotech</a> tab at lifescienceleader.com. Subscribe to our monthly <a href='https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/'>Business of Biotech newsletter</a>. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: <a href='https://www.linkedin.com/in/bencomer/'>https://www.linkedin.com/in/bencomer/</a>

<description>&lt;p&gt;&lt;a target="_blank" href="https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms"&gt;We love to hear from our listeners. Send us a message. &lt;/a&gt;&lt;/p&gt;&lt;p&gt;On this week&amp;apos;s episode of the Business of Biotech, Jared Bauer, Cofounder and CEO at Seek Labs, talks about his adventures in company turnarounds, and setting up Seek Labs to improve patient diagnoses and to discover and develop new treatments for infectious diseases. Jared explains the technology convergence that was needed to build Seek Labs&amp;apos; AI diagnostic and CRISPR-based therapeutics platform, an African Swine Fever proof-of-concept study that reduced viremia in pigs, mapping pathogens for rapid target design, and engaging with the FDA and global regulatory agencies.       &lt;/p&gt;&lt;p&gt;Access this and hundreds of episodes of the &lt;b&gt;Business of Biotech videocast&lt;/b&gt; under the &lt;a href='https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl'&gt;&lt;b&gt;Business of Biotech&lt;/b&gt;&lt;/a&gt; tab at lifescienceleader.com. &lt;/p&gt; &lt;p&gt;Subscribe to our monthly &lt;a href='https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/'&gt;&lt;b&gt;Business of Biotech newsletter&lt;/b&gt;&lt;/a&gt;.&lt;br/&gt; &lt;br/&gt;Get in touch with &lt;b&gt;guest and topic suggestions&lt;/b&gt;: ben.comer@lifescienceleader.com&lt;br/&gt;&lt;br/&gt;Find &lt;b&gt;Ben Comer&lt;/b&gt; &lt;b&gt;on LinkedIn&lt;/b&gt;: &lt;a href='https://www.linkedin.com/in/bencomer/'&gt;https://www.linkedin.com/in/bencomer/&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;/p&gt;</description>

We love to hear from our listeners. Send us a message.  On this week's episode of the Business of Biotech, Jared Bauer, Cofounder and CEO at Seek Labs, talks about his adventures in company turnarounds, and setting up Seek Labs to improve patient diagnoses and to discover and develop new treatments for infectious diseases. Jared explains the technology convergence that was needed to build Seek Labs' AI diagnostic and CRISPR-based therapeutics platform, an African Swine Fever proof-of-concept ...

Company Turnarounds And AI For Infectious Diseases With Seek Labs' Jared Bauer

<a target="_blank" href="https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms">We love to hear from our listeners. Send us a message. </a>On this week&apos;s episode of the Business of Biotech, we&apos;re speaking with Cindy Perettie, Executive Vice President and Global Head at Kite Pharma, a Gilead-owned company focused on curing cancer with cell therapies. Perettie talks about scaling cell therapies in the community setting, global manufacturing strategy, preparing for the launch of late-stage development programs in lymphoma and multiple myeloma, and working with partners like Arcellx. She also discusses cell therapy funding cycles and big pharma, the autologous versus allogeneic divide, why in vivo CAR-T therapies could be a game changer, what the FDA&apos;s focus on cell and gene therapies could mean for U.S. competition, and more. Access this and hundreds of episodes of the Business of Biotech videocast under the <a href='https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl'>Business of Biotech</a> tab at lifescienceleader.com. Subscribe to our monthly <a href='https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/'>Business of Biotech newsletter</a>. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: <a href='https://www.linkedin.com/in/bencomer/'>https://www.linkedin.com/in/bencomer/</a>

<description>&lt;p&gt;&lt;a target="_blank" href="https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms"&gt;We love to hear from our listeners. Send us a message. &lt;/a&gt;&lt;/p&gt;&lt;p&gt;On this week&amp;apos;s episode of the Business of Biotech, we&amp;apos;re speaking with Cindy Perettie, Executive Vice President and Global Head at Kite Pharma, a Gilead-owned company focused on curing cancer with cell therapies. Perettie talks about scaling cell therapies in the community setting, global manufacturing strategy, preparing for the launch of late-stage development programs in lymphoma and multiple myeloma, and working with partners like Arcellx. She also discusses cell therapy funding cycles and big pharma, the autologous versus allogeneic divide, why in vivo CAR-T therapies could be a game changer, what the FDA&amp;apos;s focus on cell and gene therapies could mean for U.S. competition, and more. &lt;/p&gt;&lt;p&gt;Access this and hundreds of episodes of the &lt;b&gt;Business of Biotech videocast&lt;/b&gt; under the &lt;a href='https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl'&gt;&lt;b&gt;Business of Biotech&lt;/b&gt;&lt;/a&gt; tab at lifescienceleader.com. &lt;/p&gt; &lt;p&gt;Subscribe to our monthly &lt;a href='https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/'&gt;&lt;b&gt;Business of Biotech newsletter&lt;/b&gt;&lt;/a&gt;.&lt;br/&gt; &lt;br/&gt;Get in touch with &lt;b&gt;guest and topic suggestions&lt;/b&gt;: ben.comer@lifescienceleader.com&lt;br/&gt;&lt;br/&gt;Find &lt;b&gt;Ben Comer&lt;/b&gt; &lt;b&gt;on LinkedIn&lt;/b&gt;: &lt;a href='https://www.linkedin.com/in/bencomer/'&gt;https://www.linkedin.com/in/bencomer/&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;/p&gt;</description>

We love to hear from our listeners. Send us a message.  On this week's episode of the Business of Biotech, we're speaking with Cindy Perettie, Executive Vice President and Global Head at Kite Pharma, a Gilead-owned company focused on curing cancer with cell therapies. Perettie talks about scaling cell therapies in the community setting, global manufacturing strategy, preparing for the launch of late-stage development programs in lymphoma and multiple myeloma, and working with partners like Ar...

Bringing Curative Cell Therapies To Market with Kite Pharma's Cindy Perettie

The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Life Science Connect.

Business Of Biotech

Details

Recent Episodes